Abstract: Fibrosis is a hallmark histologic event of chronic liver diseases and is characterized by the excessive accumulation and reorganizationoftheextracellularmatrix(ECM).Thegoldstandardforassessmentoffibrosisisliverbiopsy.Asthisprocedurehas variouslimitations,includingriskofpatientinjuryandsamplingerror,anon-invasiveserummarkerforliverfibrosisisdesirable.The increasing understanding of the pathogenesis of hepatic fibrosis has suggested several markers which could be useful indicators of hepaticfibrogenesisandfibrosis.Thesemarkersincludeserummarkersofliverfunction,ECMsynthesis,fibrolyticprocesses,ECM degradation and fibrogenesis related cytokines. Recently, neo-epitopes, which are post-translational modifications of proteins, have beensuccessfullyusedinboneandcartilagediseaseswhicharecharacterizedbyextensiveECMremodeling.Increasingnumbersof studiesarebeingundertakentoidentifyneo-epitopesgeneratedduringliverfibrosis,andwhichultimatelymightbeusefulfordiagnosingandmonitoringfibrogenesis.Todate,themetalloproteinasesgeneratedfragmentofcollagenI,III,IVandVIhavebeenproventobe elevatedintworatmodelsoffibrosis.Thisreviewsummarizestherecenteffortsthathavebeenmadetoidentifypotentiallyreliablenoninvasiveserummarkers.WeusedtherecentlyproposedBIPED(Burdenofdisease,Investigative,Prognostic,Efficacyand Diagnostic) systemtocharacterizepotentialserummarkersandneo-epitopemarkersthathavebeenidentifiedtodate.
Introduction
Chronicliverdiseasesaremajorglobalhealthproblemscausingapproximately800,000deathsperyear worldwide.
1,2 Liverfibrosisisthecommonpathologic processofallchronicliverdiseases,regardlessofthe cause,whichresultsfromexcessiveaccumulationof extracellular matrix. 3, 4 Liver fibrosis may progress tocirrhosisandeventuallydeath.However,increasingevidencesuggeststhatevenadvancedfibrosisis reversible, 5 althoughend-stagecirrhosisis irreversible and affected patients can only survive with a liver transplant.Estimatingthecurrentdegreeoffibrosisis crucialfordeterminingwhetherthefibrosiscouldbe reversedwithtreatment.
Liverfibrosisevaluationmethodscanbedivided into those that are invasive and those that are non-invasive. 6 Liver biopsy is an invasive method that has long been regarded as the 'gold standard' forstagingliverfibrosis.Biopsyallowsphysicians toobtaindiagnosticinformationnotonlyonfibrosis,butalsoonmanyotherliver-injuringprocesses, suchasinflammation,necrosis,steatosisandhepatic depositsofironorcopper. 7 However,severalissues preventtheroutineuseofliverbiopsyasaclinical tool,includingriskofinjurytothepatient,variable accessibility of the damaged section of the liver, high cost, sampling errors and inaccuracy due to inter-and intra-observer variability of pathologic interpretations. 8 Non-invasivemethodsincludeserumandgenetic tests, and imaging techniques. In recent years, interest in identifying and describing liver fibrosis using molecular serum markers has been on the rise. Serum markers offer a cost effective alternative to liverbiopsyforbothpatientsandclinicians.Inadditiontobeinglessinvasive,thereisalowriskofsampling error and small observer-related variability. Moreover,measurementsmaybeperformedrepeatedlyovertime,allowingforongoingmonitoringof fibrosis. 9 However, there are many limitations for serum biomarkers. They are not liver-specific and haveatendencytobemoreelevatedinthepresence ofinflammation.Inaddition,serummarkerreadings maybefalselyhighduetotheirlowclearancerates, which are influenced by dysfunction of endothelial cells, impaired biliary excretion or renal function. Until now, most serum biomarkers have only been used as investigative, rather than diagnostic, parameters in the clinic. 10 This review describes majormolecularserummarkersofliverfibrosisand their limitations.
Classifications of Serum Markers
Nobiomarkersarecurrentlyavailabletoreplaceliver biopsyintheevaluationofliverfibrosis.Onepossible reasonisanimpreciseandconfusingclassificationof potential biomarkers. Most commonly, fibrosis biomarkersareclassifiedinoneoftwoclasses.ClassI fibrosismarkersaredirectserummarkers,whichare molecules derived from ECM turnover reflecting the activity of the fibrotic process, and are thought toindicatetheextentofconnectivetissuedeposition. Class II biomarkers are indirect serum fibrosis biomarkersthathavebeenusedinclinicalpractice,and havebeenidentifiedfromretrospectivestudies.They are calculated by mathematical algorithms, and do not necessarily reflect ECM turnover and/or fibrogenic cell changes.
11
Adisadvantageofthissecondclassificationisthatitdoesnotprovideinformationabout thepotentialclinicaluseoftheindividualserumbiomarkersthatwereusedinthealgorithm,nordoesit go far enough in terms of recognizing, differentiating and understanding them.
12

Hepatic Fibrogenesis and its Molecular serum Markers
Mechanisms of hepatic fibrogenesis
Liver fibrosis is the final common stage of most chronicliverdiseases,whichistriggeredbychronic liver injury and develops from a series of events includingapoptosisornecrosis,inflammation,tissue remodelingandrepairprocesses.Hepatocytesarethe mostabundantcellsinliver.Theirapoptosisisprominentinliverinjuryandcanbeidentifiedinvirtuallyall formsofliverinjury. [13] [14] [15] [16] [17] [18] [19] Someproteinsarereleased fromdamagedhepatocytesandtheirlevelsinserum canreflectliverfunction.Afterliverinjury,therepair processoccurs,whichcantakeeitheroftwodistinct paths:aregenerativepath,inwhichinjuredcellsare replacedbythesametypeofcells;orapathknown asfibroplasiasorfibrosis,inwhichconnectivetissue replacesnormalparenchymaltissueinanuncontrolled fashion.Repeatedinjuryanduncontrolledrepairprocessesresultinsubstantialdepositionofextracellular matrix(ECM)componentsinwhichnormaltissueis replacedbyscartissue. [20] [21] [22] [23] Basic research has explored the mechanisms of hepatic fibrogenesis, as shown in Figure 1 . Hepatic stellatecells(HSCs)arethekeyfibrogeniccellsand their'activation'isthedominanteventin fibrogenesis. Activation of HSCs refers to the conversion of quiescent, vitaminA-storing cells into proliferative, fibrogenicandcontractilemyofibroblastswhichcan synthesizeandsecretelargeamountsoffibril-forming collagens,particularlycollagentypeIandIII.
5, 24 The activation of HSCs is a complex but tightly programmedresponsetoliverinjury.Theearliestchanges inHSCsreflectparacrinestimulationbyallneighboring cells, including Kupffer cells, hepatocytes and leukocytes, while autocrine cytokines (including transforminggrowthfactorβ(TGF-β) and connective tissuegrowthfactor(CTGF))playvitalrolesinregulating and maintaining their activation. 25, 26 Damaged hepatocytesreleasecytokines(TGF-β, tumor necrosis factor α(TNF-α),epidermalgrowthfactor(EGF)
andinsulin-likegrowthfactor(IGF))responsiblefor theactivationofKupffercellsandtherecruitmentof activatedT-cells.ActivatedKupffercells,T-cellsand damaged hepatocytes also release the inflammatory cytokines (TNF-α, interferon γ (INF-γ), IL-6), free radicalsandgrowthfactors(platelet-derivedgrowth factor (PDGF), CTGF) which further promote HSC activationand proliferation. Since the cytokines are closelyrelatedwithfibrogenesis,theypossiblycould beusedasbiomarkersforliverfibrosis.
LiverfibrosisischaracterizedbyexcessiveECM accumulationwhichresultsfrombothincreasedsynthesisanddecreaseddegradationofECM.Initiating events in stellate cell activation occur in the background while progressive changes are taking place in the surrounding ECM within the sub-endothelial spaceofDisse.Overtime,thesub-endothelialmatrix compositionchangesfromonecomprisedoftypeIV collagen and laminin to one rich in fibril-forming collagens, especially collagen type I and III.
4
The pro-peptide or the mature protein of collagen types I and III can be used as biomarkers for liver fibrosis. There are two kinds of ECM degradation during hepatic fibrogenesis. One involves the basementmembrane(comprisedofcollagentypeIV)and is called pathologic matrix degradation. 5 Thus, the proteinfragment(aneo-epitope)ofmatrixdegradationcouldbeusedasabiomarkerforliverfibrosis. The other type involves excess fibril-forming collagen and is called restorative matrix degradation. 5 In theextracellularspace,matrixdegradationoccursas a consequence of the action of a family of enzymes calledmatrixmetalloproteinases(MMPs).Theactive formsoftheseMMPscanbeinhibitedbytissueinhibitorsofmatrixmetalloproteinases(TIMPs),whichare importantregulatorymoleculesintissueremodeling andrepairandactbybindingwithMMPs.Through this combination of mechanisms, extracellular matrix degradation is closely regulated. 27 Activated HSCs alsoproduceMMP-2,MMP-9andMMP-3,whichdisruptthebasementmembrane,allowinginflammatory cellstobeeasilyrecruitedtothesiteofinjury. 23, [28] [29] [30] [31] [32] ThelevelsofMMPsandTIMPsarecloselyrelatedto liverfibrosisandcouldpossiblybeusedasbiomarkersforliverfibrosis.
These events of pathogenesis of hepatic fibrosis have indicated some potential serum markers of hepaticfibrogenesisandfibrosis( Fig. 1 and Table 2 ).
Potential molecular serum markers of liver fibrosis
Serum markers of liver function Sincefibrosisistheresultofliverinjury,serummarkersofliverfibrosiscouldindicatethedegreeofliver damage and function. These markers are easy to measure as they are based on routine laboratory tests conducted in a hospital. Serum alanine aminotransferases (ALT) are released from liver tissue into the circulation in proportion to the degree of hepatocellular damage, 33 and their level is thought to be one of the most sensitive markers of liver injury and liver diseaseprogression.
34-36
Serumaspartateaminotransferases(AST)levelsareevenmoreimportantpredictorsofhistologicalactivitythanALT, 37, 38 and the ratio ofAST/ALT. 1(AAR)hasbeenproposedasatestof cirrhosis. 39, 40 However,thediagnosticaccuracyofthis ratio is highly variable among different studies. [41] [42] [43] Serum markers of eCM synthesis Liverfibrosisisassociatedwithmajoralterationsin bothquantityandcompositionofECM. 44 Inadvanced stages,thelivercontainsapproximately6timesmore ECM components than normal, including collagen type I, III, and IV, fibronectin, undulin, elastin, laminin, hyaluronan, and proteoglycans.
1 Therefore, someparametersrelatedtoelevatedECMsynthesis couldbeusedasmarkersofliverfibrosis.
Collagens are synthesized by HSCs as precursor moleculeswithlargepro-peptideextensionsatboth theN-andC-terminalends. 45 Thematurepro-peptide arecleavedfrompro-collagenbyN-andC-terminal proteinases,andthematurecollagenisthenintegrated into the ECM. Both the pro-collagen and the propeptidereflectthesynthesisofECM.TheN-terminal pro-peptideofcollagentypeIII(PIIINP)isthemost widelystudiedmarkerofliverfibrosis.
46,47
Itisuseful todetectcirrhosiswithasensitivityofabout94%and specificityofabout81%,whichcanbeincreasedup to93%ifcombinedwithadditionalserummarkers. 48 PIIINP has achieved a limited clinical application, butnotwidespreadacceptance.
49 Inchronichepatitis C(CHC)patients,PIIINPlevelshavenotbeenshown tocorrelatewiththedegreeoffibrosisbutdocorrelate with scores for necrosis. 50, 51 PIIINP levels are knowntobeelevatedinacuteandchronicactivehepatitis and correlate with aminotransferase levels.
52,53
HoweverPIIINPisnotspecificforliverfibrosisasits levelsarealsoelevatedinlungfibrosis,chronicpancreatitisandrheumatoidarthritis(RA).
54-57 Therefore PIIINPismorelikelyamarkerofinflammationthan offibrosis. TypeIVcollagenisregardedasaputativemarker ofbasementmembraneformationandsinusoidscapillarization, which are important pathological processesinfibrosisdisease.TheserumlevelsoftypeIV collagencanbeusedforpredictingthestateofliver fibrosis, 58, 59 and they are also increased in alcoholic liver diseases and in hepatocellular carcinoma.
60
P4NP 7S, the N-terminal pro-peptide of type IV collagen7Sdomain,issignificantlyelevatedinrats with liver fibrosis detected by histology in the bile ductligation(BDL)andcarbontetrachloride(CCl 4 )-inducedliverfibrosismodels,andiscorrelatedwith increasedhepatictypeIVcollagenexpressioninBDL rats. 61 The N-terminal pro-peptide of collagen type I (PINP) has been shown to be associated with the developmentofliverfibrosis,butnotbone formation, inadultratssubjectedtoBDL.
62 Thus,PINPmaybe useful in studying the pathogenesis of liver fibrosis.However,cautionshouldbeappliedwheninterpreting PINP levels in other disease states such as inflammation.
63
Increased serum levels of PVCP-1230, the propeptideofcollagentypeV,havebeendemonstrated to beassociatedwiththeextentof collagendepositionintwodifferentmodelsoffibroticprocessesin theliver.ThedataindicatethatformationoftypeV collagenmaybeofvalueasadisease-specificdiagnosticbiomarkerthatreflectsthetotalburdenofliver disease. 64 Hyaluronan (HA) is a glycosaminoglycan synthesized by HSCs and it is a component of the ECM. 65 High levels of HA in serum may reflect increased synthesis of ECM by HSCs, and it appears to be the best individual test that reflects ECM concentration. [66] [67] [68] Since the negative value of HA in serum at a cut-off value of 60 µg/ml is much higher (98%-100%) than the positive value (61%), it can be used to exclude advanced fibrosis and cirrhosis. 54, 69 However, HA levels may be elevatedfromnon-hepaticsourcessuchaschronic inflammatoryprocesses,asinrheumatoidarthritis, and after meal or glucose drink.
70,71
YKL-40 is a 39-kilodalton glycoprotein that is involved in remodeling of the ECM. 72 Itisclaimed that the serum level of YKL-40 is closely related to the degree of liver fibrosis. 73 YKL-40 has been tested in HCV-patients showing a sensitivity and specificityofaround80%andanAUROCof0,81 forfibrosis. 74 Inthosewithalcoholicliverdisease, a specificity of 88% and sensitivity of 51% have been reported. 72 A study of YKL-40 in alcoholic liver disease has suggested that it could function as a marker of clinical outcomes. 46 The limitations of YKL-40 persist largelydue to its ubiquitous presenceandthereforeitcannotbeconsideredaliverspecificmarker.
75
Microfibrillar-associated protein 4 (MFAP-4) is a ubiquitous protein which is a ligand for integrins and plays a potential role in ECM turnover during fibrogenesis. The serum levels of MFAP-4 weredetectedinalargenumberofpatientsincluding 139 patients with different hepatic fibrosis stages on HCV infection. The results showed that MFAP-4couldbeanovelcandidatebiomarkerdue to its high accuracy in distinguishing healthy versus cirrhotic livers (AUC = 0.97, P , 0.0001) as wellasstage0 versusstage4fibrosis(AUC=0.84, P ,0.0001),andstages0to3versusstage4fibro-sis(AUC=0.76,P ,0.0001). 76 However,aswith YKL-40,ubiquitouspresenceofMFAP-4excludes its possible use as a liver-specific marker, unless changes in other related diseases are investigated and excluded.
Serum markers of fibrolytic processes
In the fibrotic liver there is a net deposition of fibrillar matrix, predominantly of collagen type I and III. Interstitial collagenases (MMP-1 in human and MMP-13 in rat) are the main enzymes which degrade collagen types I and III through cleaving the α-chain at a specific Gly-Ile/Leu site. Circulating MMP-1 concentrations are significantly reduced,whileTIMP-1levelsarehigher,asfibrosis gradesincreaseinhepatitisCinhumans. 77 However, astudyperformedonaratfibrosismodelshowedthat the level of MMP-13 did not change but remained ataconstantlevelthroughoutthefibrosisregression phase, while the level ofTIMP-1 decreased rapidly andsignificantly,indicatingthatTIMP-1reductionis associatedwithapoptosisofactiveHSCs. 78 Intheearlystageoffibrosis,MMPscandegrade normal basal membranes and this may contribute to thepathogenesisofliverfibrosis.
27 Thetwomostrelevant MMPs are gelatinaseA (MMP-2) and gelatinase B (MMP-9). MMP-2 is secreted by activated HSCs, and MMP-9 is mainly secreted by activated Kupffer cells. In the progression of liver fibrosis, MMP-2isalsoinvolvedinthedegradationoffibrotic matrix. 79 Both MMP-2 and MMP-9 are correlated with fibrosis, 77 but some studies examining the correlation of MMP-2 with chronic HCV have yielded contradictory results. 80 ThestudybyBoekerandcoworkers 81 showsthatTIMP-1andMMP-2levelsare accurateindetectingcirrhosisinpatientswithHCV (sensitivity of TIMP-1 levels, 100%; specificity, 56%-75%;AUCforMMP-2levels,0.97).However theyarenotcapableofdifferentiatingbetweenmild andmoderatefibrosis(AUCof0.71forTIMP-1and 0.59 for MMP-2), therefore their clinical utility has been demonstrated only in advanced stages of liver fibrosis.
Serum markers of eCM degradation (neo-epitopes) ECM degradation mediated by MMPs can occur at differentstagesoffibrosis.Intheearlystageofliver fibrosisthedegradationofbasalmembranesoccurs, whilethedegradationoffibroticmatrixcharacterizes theprogressionofthedisease.
27 TheproductsofdegradationoftheECM,theso-calledneo-epitopes,may reflectdifferentstagesofthefibrosisandthusmaybe used as markers.
Neo-epitopes are post-translational modifications (PTMs) of proteins generated by protease cleavage, citrullination, nitrosylation, glycosylation and isomerization.Eachmodificationresultsfromaspecificlocalphysiologicalorpathobiological process. 82 A range of protease-generated neo-epitopes has already been described in the literature, but they havenotyetbeenusedinappliedsciencetodevelop quantifiable methods of disease assessment. In the contextofboneandcartilagediseases,neo-epitopes of collagen types I and II as well as aggrecan have been well described. 83, 84 Preliminary neo-epitopes generated during the process of liver fibrogenesis havebeeninvestigated,andhavebeenprovedtobe elevated in CCl 4 -rats and BDL-rats. [85] [86] [87] [88] [89] The levels of the MMP-9 generated fragment of collagen type III,CO3-610,havebeenshowntocorrelatewiththe degreeofliverfibrosisinratsduringtheprogression phaseoffibrosis,butnotwiththelevelsoftotalcollagenduringregression,indicatingCO3-610isapoten-tialmarkerofprogressionratherthanregression.The steep elevationofCO3-610levelsappearedasearly as 4 weeks after initiating treatment with CCl 4 in the rat model of liver fibrosis, following a progressive increase in total collagen and collagen type III levels.
87
In addition, raised CO3-610 levels closely reflect portal hypertension in experimental liver fibrosisinrats. 86 Thesefindingsunderlinethepotentialprognosticcapacityofthisnovelmarkerforliver fibrosis. 85, 87 CO6-MMP,acollagentypeVIfragment generatedbyMMP-2and-9,wasdemonstratedtobe elevatedinbothBDLandCCl 4 rat models. Aspecific peptide sequence, 1438'GTPSVDHGFL'1447 (CO4-MMP), in the α 1 chain of type IV collagen generatedbyMMP-9,wassignificantlyincreasedin the serum of all BDL rats compared with baseline, withamaximumincreaseof248%seentwoweeks afterBDL. 88 IntheCCl 4 model,levelsofCO4-MMP were significantly elevated at weeks 12, 16 and 20 comparedto baselinelevels,withamaximumincrease of88%after20weeks.CO4-MMPlevelscorrelated to Sirius red staining results of CCl 4 induced liver fibrosis.
88
CO1-764,atypeIcollagenfragmentgeneratedbyMMP-2,-9and-13cleavage,waselevatedin liverfibrosisbutnotinpatientswithprostate-, lung-or breast cancer with skeletal metastases, and appears not to be derived from bone breakdown. 90 These datafurtherindicatethehighpotentialfortheuseof neo-epitope biomarkersspecificforliverfibrosis.
Since many ECM components, as well as enzymes responsible for remodeling, are present in different tissues, further identification of liver-and fibrosis-specificneo-epitopesisneededfortheiroptimal application in liver fibrosis monitoring, assessmentandinthecharacterizationofthepathogenesis. The proteolytic action of MMPs results in the generationofspecificcleavagefragments,anddifferent MMPshavedifferentfunctionsatdifferentstagesof fibrosis. Therefore, the combination of MMPs and specificcleavageproductsoftheECMcouldenhance the sensitivity and specificity of neo-epitopes 82 and produce a more specific indication of the specific stage of liver fibrosis. The combination of serum markers of ECM synthesis and degradation, such as CO3-610andPIIINP,CO4-MMPandPIVCP,PINP and CO1-764, can also be used to investigate the pathogenesisofdifferentstages.
Serum markers of fibrogenesis-related cytokines
Unregulated cytokine synthesis and release contribute to the initiation, progression and maintenance of fibrosis. 91 Some cytokines thought to mediate hepatic fibrogenesis have been studied as potential markers of fibrosis. However, only a few studies have addressed the diagnostic accuracy of fibrosisassociated cytokines, and showed that they are less valuablemarkersthanECMcomponents.
TGF-β is the major stimulus for HSCs to synthesize ECM. TGF-β concentrations in plasma are elevated in, and correlate with the severity of, liver disease and were suggested as non-invasive biomarkers of fibrosis. TGF-β has been shown to correlate well with the presence of liver fibrosis in patients with alcoholic liver disease (ALD) and HCV. 92 However,itsreleaseisinjury-dependentand correlates withALT andAST. 93, 94 Therefore it was suggestedasamoreappropriatemarkerofnecrosis ratherthanfibrogenesis.TNF-α and its induction of IL-6,-8and-18areassociatedwithalcoholicfibrosis andtheymayalsopredictclinicaloutcome.
95 TNF-α and IL-4 levels correlated more closely in chronic hepatitisBpatientsthaninthecontrols.
96 PDGFisa potentfibrogenicgrowthfactorknowntosynergize with TGF-β. 97 PDGF, mainly produced by Kupffer cells,isthepredominantmitogeninducingmigration and proliferation of mesenchymal cells including HSCstothesiteofinjury. 98 SerumlevelsofPDGF have shown high potential as markers for fibrosis progression.
99
CTGF is another important fibrogenic factor whichissynthesizedbybothHSCsandhepatocytes andisstronglydependentonTGF-βpresence. 100, 101 CTGF is a general mediator of fibre-fibre, fibrematrix, as well as matrix-matrix interaction. It is proposed as a fibrogenic 'master switch' in the epithelial-to-mesenchymal transition which plays akeyroleintheincreaseofECM-producingfibroblasts during liver fibrosis. 101 A recent preliminary study reported not only a significant elevation in circulatingCTGFinpatientswithfibrosis,butalso a correlation with fibrogenesis.This study showed CTGF levels decreased in fully developed, endstage cirrhosis,inwhichtheprocessoffibrogenesis is almost terminated. Thus, CTGF has been suggestedasavaluablebiomarkerofactive fibrogenesis. Serum CTGF is also suitablefordetermininghepatic fibrosisanditisapowerfulmarkerinpatientswith chronicHCVinfection.
102,103 serum Marker Model of Liver Fibrosis
Currently,noefficientandaccuratemarkersoffibrosisdiagnosis,stagingandprognosisexist.Numerous attempts have been made to identify non-invasive markersthatarecapableofprovidingaccurateinformation about fibrogenesis and the extent of fibrosis in the liver, and others have examined the combination of several parameters indicating fibrogenesis. The most widely known combined parameters are discussedbelow.
AST/ALT
AST andALT are hepatic enzymes elevated in the bloodbeforetheclinicalsignsandsymptomsofliver diseasesappear.Theratioofthesetwoenzymeswas firstmentionedbyNaikiMinthestudyofTyzzer's disease, 104 and has been found useful in evaluation ofchronicviralhepatitis.
35 TheratioofASTtoALT tends to increase with advancing stages of fibrosis from approximately 0.8 in healthy subjects.The greatest value of this ratio is that it is suitable for the non-invasivediagnosisofcirrhosis,wherearatioof morethan1suggeststhepresenceofcirrhosis. 105, 106 However, the AST/ALT ratio is confounded when used in alcoholic and many other acute and chronic fattyinfiltratingliverdiseases. 107 For this reason, the ratio is not recommended for evaluating the stage of fibrosis.
APRI
TheAST-to-plateletratioindex(APRI)iscalculated as(AST/upperlimitofnormalrange)/plateletcount (10 9 /L) × 100. This index was first put forward by Waiandco-workers 108 usingtoidentifyCHCpatients with significant fibrosis and cirrhosis with a high degree of accuracy. Application of this index may decreasetheneedforstagingliverbiopsyspecimens among CHC patients. Several later studies in CHC showed the major strength of theAPRI is that it is able to exclude significant HCV-related fibrosis, 109 butarecentlargemeta-analysissuggestedthatAPRI canidentifyhepatitisC-relatedfibrosiswithamoderate degree of accuracy.
110
Fibrotest
Thefibrotestisacompositeoffiveserumbiochemicalmarkers(alpha-2-macroglobulin,apolipoprotein A1, haptoglobin, γ-glutamyl transpeptidase, and bilirubin) associated with hepatic fibrosis developed byPosynardandco-workers.
111 Itgeneratesascore thatiscorrelatedwiththedegreeofliverdamagein people with a variety of liver diseases. Due to the variability of components of assays and analyzers, fibrotest assays can only be performed in validated laboratories. 112 The test has been validated by multiple groups in several liver diseases, including chronichepatitis. [113] [114] [115] [116] Althoughpreliminaryresults are encouraging, frequently cited limitations include the assay cost, failed external validation, difficulty in differentiating intermediate fibrosis stages, and the inability to exclude other conditions such as steatosis.
Biomarker Insights 2012:7 Fibrometer
Fibrometer is an algorithm combining a number of parameters including number of platelets, prothrombintime,AST,α2-macroglobulin,hyaluronate, urea and age. 118 The performance of Fibrometer for the detection of late fibrosis was compared to five other well described algorithms in 180 hepatitis C patients.
119
Theoveralldiagnosticscoreswereevaluated by theAUROCs ranging from 0.86 for Fibrometer to 0.78 for Forns' score (not significant) for the discrimination of F0F1 from F2F3F4. For the discriminationofF0F1F2fromF3F4,theAUROC's ranged from 0.91 for Fibrometer to 0.78 for Forns' score.Furthermore,extensivefibrosiswaspredicted in10%-86%ofpatients.
eLF
The Enhanced Liver Fibrosis (ELF) algorithm includeshyaluronicacid,theN-terminalpro-peptide of type III collagen, and tissue inhibitors of matrix metalloproteinase. The algorithm detected fibrosis (sensitivity, 90%) and accurately detected the absenceoffibrosis(negativepredictivevalueforsignificantfibrosis,92%;AUROC,0.804).Performance wasexcellentforalcoholicliverdiseaseandnonalcoholic fatty liver disease. 47 In a study of patients withprimarybiliarycirrhosis,theevent-freesurvival wassignificantlylowerinthosewithahighbaseline ELF than those with a low baseline. Each 1-point increaseinELFwasassociatedwitha3-foldincrease in future complications. The researchers concluded that the ELF algorithm is a highly accurate noninvasive measure of the severity of primary biliary cirrhosiswhichalsoprovidesusefullong-termprognostic information. 120, 121 In pediatric patients with non-alcoholicfattyliverdisease(NAFLD),theELF testpredictedliverfibrosisstagewithahighdegree of sensitivity and specificity (AUROC of 0.92 for fibrosisstage1,0.98forstage2,and0.99forstage3, respectively);resultsweresuperiortothosereported for adults. 122 ThekeycomponentsoftheELFalgorithm are expressed during early stages of collagen deposition in the liver, and this is most likely the reason why ELF retains its prognostic ability eveninearlystagesofthediseaseprocess(AUROC 0.737-0.863 at all time points). However, because thetestusesdirectmarkersoffibrogenesis(HAand TIMP-1), the results will be unreliable in patients with chronic diseases characterized by fibrogenesis in organs other than the liver.
123
BIPED Classification
The Burden of disease, Investigative, Prognostic, Efficacy of intervention and Diagnostic (BIPED) classification (Table 1) has been recently proposed to assess biomarkers used in clinical trials and in research and development. 124 Classification by the BIPED system may enable biomarker researchers working in different disease areas to communicate and compare results in a robust framework. This should lead to consistency in the assessment of sensitivityandspecificityofdifferentbiomarkers.
In Table 2 , the serum markers described in this reviewareclassifiedfollowingtheBIPEDmethods.
Discussion
Atpresent,themoststudiedbiomarkersforliverfibrosis are represented by the products of extracellular matrix synthesis and degradation, and by the enzymes that regulate their production or modification, such as hyaluronic acid, matrix metalloproteinases, their inhibitors TIMPs and cytokines such as TGF-β. 
Burden of disease (B)
Burden-of-disease markers assess the severity or extent of disease, typically at a single point in time, among individuals with a certain disease.
Investigative (I)
An investigative marker lacks sufficient information to allow its inclusion in one of the existing biomarker categories.
Prognostic (P)
The key feature of a prognostic marker is the ability to predict the future onset of a disease. Efficacy of intervention (E) Information about the efficacy of treatment among persons with a certain disease or those at high risk for its development. Diagnostic (D) Diagnostic markers are defined by the ability to classify individuals as either having or not having a disease.
Extracted from Bauer et al.
124
Some of the biomarkers discussed in this paper reflectfibrosisprogressionandothersfibrosisregression, and so could evaluate different stages of liver fibrosis.Neverthelessnoneofthesemoleculescompletely fulfilltherequirementsofanidealbiomarker, mainly because of their lack of sensitivity in identifyingpatientswithamilddegreeoffibrosisbutwho are at risk of progression. Moreover these markers areoftennotspecific,becausetheycanbedetected in organs other than liver and can be affected by otherpathologicalconditions,suchasrenalorliver failure.
125
Liver biopsy is currently the 'gold standard' for assessing liver disease and fibrosis. However, it is invasive, has the potential to cause side-effects, it issubjecttosamplevariations,andisseldomafirst choice in the clinic. Use of this test could be reduced with a combination of routine laboratory tests and fibrosis biomarkers capable of accurately detecting the presence of cirrhosis. However most markers identified so far have been evaluated in only small cohorts of patients. Some assays for measuring the markershaveincludedsomesubjectivevariablesor laboratory tests that are costly and not readily available,andveryfewmoleculeshavebeensatisfactorily validated. Therefore, neither single biomarker nor parametercanatpresentsubstituteliverbiopsy.
Intheclinic,mostpatientswithchronicliverdiseasewillprogresstocirrhosisiftheyarenottreated correctlyandattheappropriatetime.Cirrhosisisthe end-stageofchronicliverdiseases,causingincreased morbidity and complications such as portal hypertension,developmentofesophagealvarices,ascites, encephalopathy,varicealhemorrhageandhepatocellular carcinoma, 5, 23 andultimatelydeath,whichonly canbeavoidedbylivertransplantation.
126
Routineclinicaltestsandinspections,suchasliver function evaluation, coagulation index, blood cell counts, abdominal ultrasound and Fibroscan, are normally used to monitor and assess the state of chronic liverdiseases.However,amosthelpfuldiagnostictool wouldbetheonethatenablestheclinicianto identify based on measurement of neo-epitopes, which are special pathologically generated fragments of proteins released during extracellular remodeling, may assistinisolatingtheidealbiomarker,whichmaybe usedeitheraloneorincombinationwithothervalidated biochemical markers.
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